Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
NCT02765802 is registered in ClinicalTrials.gov with EIT Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
- Lead sponsor
- EIT Pharma, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 19, 2016
- Completion date
- December 12, 2018
- Enrollment
- 33 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.